Global Cell-Based Assays Market

Global Cell-Based Assays Market Size, Share, Growth Analysis, By Products & Services(Reagents, Assay Kits), By Application(Basic Research, Drug Discovery), By End-Use(Pharmaceutical and Biotechnology Companies, Academic & Research Institutes) - Industry Forecast 2024-2031


Report ID: SQMIG35H2154 | Region: Global | Published Date: March, 2024
Pages: 219 | Tables: 100 | Figures: 66

Global Cell-Based Assays Market Insights

Global Cell-Based Assays Market size was valued at USD 17.6 billion in 2022 and is poised to grow from USD 19.14 billion in 2023 to USD 37.44 billion by 2031, growing at a CAGR of 8.75% during the forecast period (2024-2031).

The global research landscape, including major clinical trials and drug discovery efforts, was profoundly disrupted by the COVID-19 pandemic. To address research backlogs, researchers worldwide swiftly adopted efficient and time-sensitive methodologies. Moreover, a multitude of cell-based assays were specifically developed for detecting COVID-19 infections, with several tests gaining FDA approval for global emergency use. An illustrative example is the T-Detect COVID-19 routine T-cell test (by Adaptive Biotechnologies), which obtained Emergency Use Authorization from the U.S. FDA in May 2021. This innovative Next-Generation Sequencing (NGS)-based test facilitates the identification of T-cells recognizing SARS-CoV-2 antigens, confirming recent infections.

Cell-based drug screening assays have played an integral role in drug discovery research, enabling the meticulous selection of promising drug candidates from vast compound libraries. The scope of these assays spans a diverse spectrum, influenced by multifaceted considerations in various drug development trajectories. Anticipated advancements in drug discovery hold promise for fostering an environment conducive to industry growth. A compelling instance is the groundbreaking development unveiled in September 2022 by Fraunhofer Institute researchers—Proxidrugs—a therapeutic prospect harnessing cell-based waste disposal systems to address conditions like infections, cancer, and Alzheimer's disease. This underscores the versatility of cell-based assays in driving scientific innovation and therapeutic evolution.

The market is currently poised for robust growth due to factors such as surging demand for drug discovery, an escalated requirement for biotechnology research, and the mounting incidence of infectious diseases, cancer, autoimmune disorders, and genetic anomalies. Cell-based assays play a pivotal role in the drug discovery process, not only for validating potential drug candidates but also for lead profiling, analyzing cellular signaling, and assessing toxicity. A prime example is The Annexin V-Cy3 apoptosis detection kit (by Cell Biologics), which leverages fluorescence to detect apoptosis—a testament to the diverse applications of these assays in comprehensive cellular analysis.

US Cell-Based Assays Market is poised to grow at a sustainable CAGR for the next forecast year.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Cell-Based Assays Market size was valued at USD 17.6 billion in 2022 and is poised to grow from USD 19.14 billion in 2023 to USD 37.44 billion by 2031, growing at a CAGR of 8.75% during the forecast period (2024-2031).

The competitive landscape of the global cell-based assays market is marked by intense innovation, strategic collaborations, and a focus on cutting-edge technology to meet the expanding demands of drug discovery, toxicology studies, and biomedical research. Industry leaders like Thermo Fisher Scientific, Merck KGaA, and PerkinElmer have established their dominance through a combination of advanced assay development, extensive product portfolios, and global reach. 'Thermo Fisher Scientific, Inc. (United States)', 'Promega Corporation (United States)', 'Merck KGaA (Germany)', 'PerkinElmer, Inc. (United States)', 'Danaher Corporation (United States)', 'Cell Signaling Technology, Inc. (United States)', 'Bio-Rad Laboratories, Inc. (United States)', 'Agilent Technologies, Inc. (United States)', 'GE Healthcare (United Kingdom)', 'Lonza Group Ltd. (Switzerland)'

The increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, and neurodegenerative disorders fuels the demand for advanced cell-based assays for disease modeling and drug testing.

3D Cell Culture Advancements: The shift towards more physiologically relevant 3D cell culture models is gaining traction, allowing better recapitulation of in vivo conditions and enabling improved drug screening and toxicity assessment.

North America stands as the dominant force globally, commanding a substantial market share, and this is attributed to its well-established healthcare sector and the widespread adoption of cell-based assays. The United States, in particular, showcases a robust healthcare landscape and a remarkable proclivity towards utilizing cell-based assays. Notably, the escalating prevalence of chronic diseases such as cancer, osteoarthritis, and diabetes within the United States fuels an augmented demand for cell-based assays, especially in the realm of pioneering drug discoveries. This phenomenon significantly contributes to the market's expansion, acting as a pivotal growth catalyst.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Cell-Based Assays Market

Product ID: SQMIG35H2154

$5,300
BUY NOW GET FREE SAMPLE